ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
Фаза 2
Прекращено
NCT03445000
| Заболевание | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | ETOP IBCSG Partners Foundation |
|---|
| Статус | Прекращено |
|---|
| Участники | 14 участн. |
|---|
| Вмешательство | Alectinib |
|---|
| Дата начала | 6.11.2018 |
|---|
| Дата завершения | 31.03.2021 |
|---|
| Публикация результатов | 26.03.2025 |
|---|
Кратко
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
Best Overall Response (BOR)
Evaluated from enrollment through study completion, up to a maximum of 28 months. · Participants
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 9 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
| Trial Treatment | 2 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.